HCW starts Medicenna Therapeutics at buy; PT $8

Medicenna Therapeutics

H.C. Wainwright initiated coverage of Medicenna Therapeutics (NASDAQ:MDNA) with a “buy” rating and price target of $8. The stock closed at $3.88 on Sept. 8.

Medicenna is an immuno-oncology company developing therapies that target cancer surface receptors as well as enhanced cytokines to modulate the immune system.

Its lead product is MDNA55, a unique fusion protein that combines an interleukin-4 receptor targeting domain, with a cytotoxic domain to deliver a lethal payload against glioblastoma multiforme (GBM) cells.

Analyst Swayampakula Ramakanth writes that the company successfully completed a Phase 2b study in 2019, which showed that patients with recurrent GBM treated with MDNA55 achieved a median overall survival of 12.4 months, representing a 72% improvement, compared with a median overall survival of 7.2 months for matched control patients treated with the standard of care.

“If approved, we believe MDNA55 could become the first therapeutic agent to demonstrate a significant survival benefit for recurrent GBM patients in over 20 years,” he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.